Back to search results

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Abroad (travel likely)RecruitingPHASE2

Conditions

High-risk Smoldering Multiple Myeloma · Smoldering Multiple Myeloma · Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Colorado Blood Cancer Institute, Denver, Colorado, United States

    Contact: Study coordinator (Jeffrey Matous, MD) · jeffrey.matous@healthonecares.com

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Irene M Ghobrial, MD) · Irene_Ghobrial@dfci.harvard.edu · 617-632-4198
    Contact: Principal Investigator (Irene M Ghobrial, MD)

  • Oregon Health & Science University, Portland, Oregon, United States

    Contact: Study coordinator (Eva Medvedova, MD) · medvedov@ohsu.edu
Study leads

  • Irene C Ghobrial, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)